Therefore, in patients with cancer, sPD‐L1 may represent an unanticipated contributing factor to the overall tumour‐induced immune suppression and acts by inhibiting circulating immune T‐cells even beyond the tumour microenvironment. The gene discussed is SPDL1; the disease is neoplasm.